Sign In
Buy BPMC
$129.46
+0 (+0%)
At Close: Oct 17, 2025
Blueprint Medicines: Q2 Earnings Insights
07:42am, Thursday, 29'th Jul 2021
Shares of Blueprint Medicines (NASDAQ:BPMC) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share were up 18.42% year over year to ($1.86), which were in line
Blueprint Medicines Reports Second Quarter 2021 Financial Results
07:00am, Thursday, 29'th Jul 2021
CAMBRIDGE, Mass., July 29, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results and provided a business update for the second quarter ended June 30, 202
MD Anderson and Blueprint Medicines Announce Strategic Collaboration to Accelerate BLU-222 Development
08:00am, Wednesday, 28'th Jul 2021
HOUSTON and CAMBRIDGE, Mass., July 28, 2021 /PRNewswire/ -- The University of Texas MD Anderson Cancer Center and Blueprint Medicines Corporation (NASDAQ: BPMC) today announced a three-year strateg
Blueprint Medicines to Report Second Quarter 2021 Financial Results on Thursday, July 29, 2021
08:00am, Thursday, 22'nd Jul 2021
CAMBRIDGE, Mass., July 22, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), today announced that it will host a live conference call and webcast at 8:30 a.m.
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:01pm, Wednesday, 07'th Jul 2021
CAMBRIDGE, Mass., July 7, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunothera
3 Biotech Stocks Ready for Big Breakthroughs Like Biogen
03:23pm, Thursday, 24'th Jun 2021
This could be a breakthrough year for these three biotech stocks, resulting in massive gains for their stockholders similar to Biogen. The post 3 Biotech Stocks Ready for Big Breakthroughs Like Biogen
Blueprint Medicines (BPMC) Gets FDA Nod for Ayvakyt in SM
12:47pm, Thursday, 17'th Jun 2021
The FDA approves Blueprint Medicines' (BPMC) lead drug, Ayvakit, for treating adult patients with advanced systemic mastocytosis.
FDA Approves Blueprint Medicines' AYVAKIT™ (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis
03:50pm, Wednesday, 16'th Jun 2021
CAMBRIDGE, Mass., June 16, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has approved AYVAKIT™ (avapritinib) f
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:01pm, Friday, 04'th Jun 2021
CAMBRIDGE, Mass., June 4, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that, effective on June 1, 2021, the Compensation Committee of Blueprint Medicines' Board
Blueprint Medicines to Present at Upcoming Investor Conferences
08:00am, Tuesday, 25'th May 2021
CAMBRIDGE, Mass., May 25, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced its participation in the following upcoming investor conferences.
CAMBRIDGE, Mass., May 19, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the presentation of updated Phase 1/2 ARROW trial data demonstrating durable clinical bene
Blueprint Medicines Appoints Percy Carter, MBA, Ph.D., as Chief Scientific Officer
08:00am, Monday, 17'th May 2021
CAMBRIDGE, Mass., May 17, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of Percy Carter, MBA, Ph.D.
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:01pm, Wednesday, 05'th May 2021
CAMBRIDGE, Mass., May 5, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that, effective on May 1, 2021, the Compensation Committee of Blueprint Medicines' Board of
Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In $591 Million Deal
05:29pm, Monday, 03'rd May 2021
CANbridge will make a $10 million upfront payment for the two Fabry and Pompe candidates. Guangzhou Link Health Pharma and Australia's George Clinical plan to form a China clinical CRO JV that will co
Blueprint Medicines (BPMC) Q1 Earnings Beat, Revenues Lag
10:31am, Friday, 30'th Apr 2021
Blueprint Medicines' (BPMC) beat estimates for earnings in the first quarter of 2021 while revenues miss the same.
